



Deferasirox

Catalog No: tcsc0901

Available Sizes
ize: 5mg
ize: 10mg
ize: 25mg
ize: 50mg
ize: 100mg
Specifications
AS No: 01530-41-8
ormula: 21 ^H 15 ^N 3 ^O 4
rathway: Others
a rget: Others
urity / Grade: ·98%
olubility: MSO : ≥ 100 mg/mL (267.84 mM)
Alternative Names: CL 670





Observed Molecular Weight:

373.36

Product Description

Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.

In Vitro: In LX-2 cells treated with 50 μ M deferasirox for 12 h, α 1(I)procollagen expression is decreased by 25%, with maximal reductions (10-fold) seen following 24-120 h of treatment. Similarly, α -smooth muscle actin (α SMA) expression is significantly lower^[1]. Deferasirox had anti-proliferative effects on HL-60 or KG-1 myeloid leukemia cell lines at a concentration as low as 5 μ M. The cytotoxicity is both dose and time dependent^[2]. The viability of both EL4 cells and L1210 cells incubated with deferasirox decrease in a concentration-dependent manner^[3].

In Vivo: The tumor is significantly smaller in the SIO mice treated with deferasirox compared with control. Mice treated with DFX showed longer survival than the other groups. Deferasirox has a survival benefit for SIO leukemia murine model in terms of iron chelation and antileukemic therapy^[3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!